Mar 28 |
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
|
Mar 28 |
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
|
Mar 25 |
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
|
Mar 18 |
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
|
Mar 18 |
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
|
Mar 18 |
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
|
Mar 15 |
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
|
Mar 15 |
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
|
Mar 13 |
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
|
Mar 7 |
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
|